Effectiveness of haemophilus influenzae type b vaccines administered according to various schedules: Systematic review and meta-analysis of observational data

Pediatric Infectious Disease Journal

Volumn 32, Issue 11, 2013, Pages 1261-1269

  Jackson, Charlotte ^a,b   Mann, Andrea ^b   Mangtani, Punam ^b   Fine, Paul ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

conjugate vaccines; Haemophilus influenzae type b; meta analysis; systematic reviews; vaccine schedules

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; OUTER MEMBRANE PROTEIN; PERTUSSIS VACCINE;

ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; HAEMOPHILUS INFECTION; HUMAN; MENINGITIS; OBSERVATIONAL STUDY; PERTUSSIS; PRIORITY JOURNAL; VACCINATION;

CASE-CONTROL STUDIES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84886952082     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182a14e57     Document Type: Article

References (56)

1. Watt JP, Wolfson LJ, O'Brien KL, et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet. 2009;374:903-911.
2. Knuf M, Kowalzik F, Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine. 2011;29:4881-4890.
3. Griffiths UK, Clark A, Gessner B, et al. Dose-specific efficacy of Haemophilus influenzae type b conjugate vaccines: a systematic review and meta-analysis of controlled clinical trials. Epidemiol Infect. 2012;140:1343-1355.
4. O'Loughlin RE, Edmond K, Mangtani P, et al. Methodology and measurement of the effectiveness of Haemophilus influenzae type b vaccine: systematic review. Vaccine. 2010;28:6128-6136.
5. World Health Organization. Initiative for Vaccine Research (IVR): Optimizing immunization schedules 2013. Available at: http://www.who. int/vaccine-research/implementation/optimize-schedules/en/index.html. Accessed April 21, 2013.
6. T heodoratou E, Johnson S, Jhass A, et al. The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality. Int J Epidemiol. 2010;39(suppl 1):i172-i185.
7. S wingler G, Fransman D, Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type B infections. Cochrane Database Syst Rev (Online). 2007:CD001729.
8. Obonyo CO, Lau J. Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2006;25:90-97.
9. Low N, Redmond SM, Rutjes AWS, et al. Comparing Haemophilus influenzae Type b Conjugate Vaccine Schedules: A Systematic Review and Metaanalysis of Vaccine Trials. Pediatr Infect Dis. 2013;32:1245-1256.
10. Gessner BD, Adegbola RA. The impact of vaccines on pneumonia: key lessons from Haemophilus influenzae type b conjugate vaccines. Vaccine. 2008;26(suppl 2):B3-B8.
11. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith G, Altman DG, eds. Systematic Reviews in Healthcare: Meta-analysis in Context. London: BMJ Books; 2001.
12. Käyhty H, Peltola H, Eskola J, et al. Immunogenicity of Haemophilus influenzae oligosaccharide-protein and polysaccharide-protein conjugate vaccination of children at 4, 6, and 14 months of age. Pediatrics. 1989;84:995-999.
13. S hehab ZM, Azimi P, Asmar BI, et al. Immunogenicity and reactogenicity of Haemophilus influenzae type b-meningococcus group B outer membrane protein conjugate vaccine in children 2-60 months of age. Scand J Infect Dis. 1991;23:763-769.
14. Bulkow LR, Wainwright RB, Letson GW, et al. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J. 1993;12:484-492.
15. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ. 2003;327:557-560.
16. Wenger JD, Pierce R, Deaver KA, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Haemophilus Influenzae Vaccine Efficacy Study Group. Lancet. 1991;338:395-398.
17. Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J. 1991;10:97-104.
18. McVernon J, Andrews N, Slack M, et al. Host and environmental factors associated with Hib in England, 1998-2002. Arch Dis Child. 2008;93:670-675.
19. McVernon J, Andrews N, Slack MP, et al. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet. 2003;361:1521-1523.
20. Fleming JA, Dieye Y, Ba O, et al. Effectiveness of haemophilus influenzae type B conjugate vaccine for prevention of meningitis in Senegal. Pediatr Infect Dis J. 2011;30:430-432.
21. S hapiro ED. Case-control studies of the effectiveness of vaccines: validity and assessment of potential bias. Pediatr Infect Dis J. 2004;23:127-131.
22. Daza P, Banda R, Misoya K, et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine. 2006;24:6232-6239.
23. Baqui AH, El Arifeen S, Saha SK, et al. Effectiveness of Haemophilus influenzae type B conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study. Pediatr Infect Dis J. 2007;26:565-571.
24. Lee EH, Lewis RF, Makumbi I, et al. Haemophilus influenzae type b conjugate vaccine is highly effective in the Ugandan routine immunization program: a case-control study. Trop Med Int Health. 2008;13:495-502.
25. Lewis RF, Kisakye A, Gessner BD, et al. Action for child survival: elimination of Haemophilus influenzae type b meningitis in Uganda. Bull World Health Organ. 2008;86:292-301.
26. Muganga N, Uwimana J, Fidele N, et al. Haemophilus influenzae type b conjugate vaccine impact against purulent meningitis in Rwanda. Vaccine. 2007;25:7001-7005.
27. Lee EH, Corcino M, Moore A, et al. Impact of Haemophilus influenzae type b conjugate vaccine on bacterial meningitis in the Dominican Republic. Rev Panam Salud Publica. 2008;24:161-168.
28. de Andrade AL, de Andrade JG, Martelli CM, et al. Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil. Int J Epidemiol. 2004;33:173-181.
29. de la Hoz F, Higuera AB, Di Fabio JL, et al. Effectiveness of Haemophilus influenzae type b vaccination against bacterial pneumonia in Colombia. Vaccine. 2004;23:36-42.
30. A degbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet. 2005;366:144-150.
31. Vadheim CM, Greenberg DP, Eriksen E, et al. Protection provided by Haemophilus influenzae type b conjugate vaccines in Los Angeles County: a case-control study. Pediatr Infect Dis J. 1994;13:274-280.
32. Jafari HS, Adams WG, Robinson KA, et al. Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. The Haemophilus Influenzae Study Group. Am J Public Health. 1999;89:364-368.
33. Loughlin AM, Marchant CD, Lett S, et al. Efficacy of Haemophilus influenzae type b vaccines in Massachusetts children 18 to 59 months of age. Pediatr Infect Dis J. 1992;11:374-379.
34. Harrison LH, Tajkowski C, Croll J, et al. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children. J Pediatr. 1994;125:571-576.
35. Bower C, Condon R, Payne J, et al. Measuring the impact of conjugate vaccines on invasive Haemophilus influenzae type b infection in Western Australia. Aust N Z J Public Health. 1998;22:67-72.
36. Kalies H, Grote V, Siedler A, et al. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany's experience after 5 years of licensure. Vaccine. 2008;26:2545-2552.
37. Kalies H, Verstraeten T, Grote V, et al. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/ Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr Infect Dis J. 2004;23:944-950.
38. Lagos R, Horwitz I, Toro J, et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J. 1996;15:216-222.
39. Madhi SA, Kuwanda L, Saarinen L, et al. Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine. 2005;23:5517-5525.
40. Madhi SA, Petersen K, Khoosal M, et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J. 2002;21:315-321.
41. Hviid A, Melbye M. Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine. Vaccine. 2004;22:378-382.
42. Hviid A, Wohlfahrt J, Stellfeld M, et al. Childhood vaccination and nontargeted infectious disease hospitalization. JAMA. 2005;294:699-705.
43. Herceg A. The decline of Haemophilus influenzae type b disease in Australia. Commun Dis Intell. 1997;21:173-176.
44. S chmitt HJ, von Kries R, Hassenpflug B, et al. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr Infect Dis J. 2001;20:767-774.
45. Ramsay ME, McVernon J, Andrews NJ, et al. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis. 2003;188:481-485.
46. Morant Gimeno A, Díez Domingo J, Rosales Marza A, et al. Vaccination against Haemophilus influenzae type b in the Valencia Community: efficacy and failure of vaccinations. An Esp Pediatr. 1998;48:352-354.
47. Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA. 2000;284:2334-2340.
48. Markey P, Krause V, Boslego JW, et al. The effectiveness of Haemophilus influenzae type b conjugate vaccines in a high risk population measured using immunization register data. Epidemiol Infect. 2001;126:31-36.
49. S cheifele DW, Halperin SA, Rubin E, et al. Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and haemophilus influenzae type B conjugate) when administered as a fourth dose at 15 to 18 months of age. Hum Vaccin. 2005;1:180-186.
50. E spinoza F, Tregnaghi M, Gentile A, et al. Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial. BMC Infect Dis. 2010;10:297.
51. Ladhani SN. Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom. Clin Ther. 2012; 34:385-399.
52. Mangtani P, Mulholland K, Madhi SA, et al. Haemophilus influenzae type b disease in HIV-infected children: a review of the disease epidemiology and effectiveness of Hib conjugate vaccines. Vaccine. 2010;28:1677-1683.
53. Daum RS, Zenko CE, Given GZ, et al. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered. J Infect Dis. 2001;184:1293-1299.
54. Southern J, McVernon J, Gelb D, et al. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol. 2007;14:1328-1333.
55. Johnson NG, Ruggeberg JU, Balfour GF, et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis. 2006;12:937-941.
56. Centers for Disease Control. Food and Drug Administration approval of use of diphtheria and tetanus toxoids and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep. 1991;40:881-882.